Market Closed -
NSE India S.E.
07:43:54 2024-05-31 am EDT
5-day change
1st Jan Change
1,000
INR
-2.32%
-7.05%
+45.12%
Sales 2024
195B
2.34B
Sales 2025 *
217B
2.61B
Capitalization
1,006B
12.07B
Net income 2024
38.6B
463M
Net income 2025 *
42.66B
511M
EV / Sales 2024
5.19
x
Net cash position
2024
*
13.47B
161M
Net cash position
2025
*
29.52B
354M
EV / Sales 2025 *
4.5
x P/E ratio 2024
26.4
x
P/E ratio 2025 *
24
x
Employees
23,026
Yield 2024 *
0.58%
Yield 2025 *
0.52%
Free-Float
24.87%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
India's pharma export sales to grow faster this year, trade body says
May. 30
RE
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research
May. 27
RE
Zydus Completes Patient Enrolment for Phase II Clinical Trial of Usnoflast in ALS Patients
May. 24
MT
Zydus Lifesciences Limited Announces Completion of Enrolment for Phase II Clinical Trial of Usnoflast, Novel Oral Nlrp3 Inflammasome Inhibitor in Patients with Amyotrophic Lateral Sclerosis
May. 24
CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Theophylline Extended-Release Tablets, 300 Mg and 450 Mg
May. 22
CI
Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988
May. 21
MT
Zydus Lifesciences Records Sharp Rise in Fiscal Q4 Consolidated Profit
May. 21
MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,070 From INR750, Keeps at Hold
May. 20
MT
Transcript : Zydus Lifesciences Limited, Q4 2024 Earnings Call, May 17, 2024
May. 17
Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024
May. 17
CI
Zydus Lifesciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024
May. 17
CI
Zydus Lifesciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
May. 17
CI
Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets
May. 12
MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
May. 10
RE
Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis
May. 09
CI
More news
1 day -2.32%
1 week -7.05%
1 month +4.89%
3 months +6.18%
6 months +56.87%
Current year +45.12%
More quotes
Managers
Title Age Since
Chief Executive Officer
44
97-07-31
Director of Finance/CFO
-
-
Chairman
71
95-05-14
Members of the board
Title Age Since
Director/Board Member
72
18-12-05
Chairman
71
95-05-14
Director/Board Member
69
97-07-31
More insiders
Date
Price
Change
Volume
24-05-31
1,000
-2.32%
2,417,167
24-05-30
1,024
-1.99%
1,517,658
24-05-29
1,045
-0.78%
1,081,054
24-05-28
1,053
-0.52%
1,516,739
24-05-27
1,058
-1.63%
1,812,394
Delayed Quote
NSE India S.E., May 31, 2024 at 07:43 am EDT
More quotes
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
More about the company
Last Close Price
1,000
INR
Average target price
998.9
INR
Spread / Average Target
-0.12%
Consensus
1st Jan change
Capi.
+45.12% 12.06B +15.91% 41.97B +22.40% 22.34B +18.48% 15.25B +16.12% 14B -9.58% 6.8B -0.05% 6.79B -8.87% 5.73B +14.18% 5.49B +4.00% 4.62B
Generic Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1